Home » Healthcare » Asia Pacific Monoclonal Antibodies Market
Asia Pacific Monoclonal Antibodies Market By Source Type (Chimeric, Murine, Humanized, Human); By Production Type (In Vivo, In Vitro); By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases, Others); By End Use (Hospital, Specialty Centers, Others) – Growth, Share, Opportunities & Competitive Analysis, 2021–2032
Asia Pacific Monoclonal Antibodies Market Overview:
The Asia Pacific Monoclonal Antibodies Market size was valued at USD 40,541.17 MN in 2021 and reached USD 64,255.32 MN in 2025. It is anticipated to reach USD 149,792.56 MN by 2032, growing at a CAGR of 10.70% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2021-2024
Base Year
2025
Forecast Period
2026-2032
Asia Pacific Monoclonal Antibodies Market Size 2025
USD 64,255.32 million
Asia Pacific Monoclonal Antibodies Market, CAGR
10.70%
Asia Pacific Monoclonal Antibodies Market Size 2032
USD 149,792.56 million
Asia Pacific Monoclonal Antibodies Market Insights
Market growth is supported by oncology biologic demand, autoimmune disease treatment expansion, antibody-drug conjugate adoption, hospital-led infusion capacity and broader use of humanized and human monoclonal antibodies.
Humanized antibodies hold a strong position because they offer lower immunogenicity than murine antibodies and are widely used across oncology and autoimmune disease treatment.
Oncology remains the leading application because cancer care increasingly uses checkpoint inhibitors, antibody-drug conjugates, bispecific antibodies and targeted monoclonal antibody combinations.
Hospitals remain the leading end-use segment because monoclonal antibodies often require specialist diagnosis, infusion infrastructure, cold-chain handling, adverse event monitoring and payer documentation.
Asia Pacific Monoclonal Antibodies Market Segment Insights
By source type
By source type, Humanized held a strong position in 2025 because many established oncology and autoimmune monoclonal antibodies use humanized formats to improve tolerability and reduce immune response risk. Human antibodies are gaining momentum as development platforms prioritize lower immunogenicity, longer treatment durability and stronger chronic therapy suitability. Chimeric antibodies remain relevant in oncology and autoimmune treatment, especially in legacy biologics and biosimilars. Murine antibodies hold a smaller share because immunogenicity concerns limit long-term use, but they remain important in diagnostics, research and selected therapeutic formats. Growth will favor Humanized and Human antibodies as clinical programs focus on safety, efficacy and long-term use.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
By production type, In Vitro held the strongest position in 2025 because commercial monoclonal antibody production increasingly relies on controlled cell culture systems, recombinant expression platforms and scalable bioprocessing. In Vitro production supports consistent quality, large-batch manufacturing, process control and regulatory documentation. It is highly relevant for oncology antibodies, autoimmune biologics and next-generation antibody formats. In Vivo production remains limited and is mainly used in research, early development or selected specialized applications. Manufacturing growth will depend on cell line productivity, bioreactor capacity, quality systems, process analytics and regional biologics manufacturing investment across China, Japan, South Korea, India and Australia.
By application
By application, Oncology held the strongest position in 2025 because monoclonal antibodies are central to modern cancer treatment. Checkpoint inhibitors, HER2-directed antibodies, CD20 antibodies, VEGF inhibitors, PD-1/PD-L1 antibodies, antibody-drug conjugates and bispecific antibodies support broad use across solid tumors and hematologic malignancies. Autoimmune Diseases remain a major application due to rheumatoid arthritis, psoriasis, inflammatory bowel disease and related immune-mediated conditions. Infectious Diseases support selected antibody therapies and prevention products. Neurological Diseases are gaining momentum through anti-amyloid and immune-mediated neurology therapies. Others include ophthalmology, transplant medicine, hematology and rare disease applications.
By end use
By end use, Hospital held the strongest position in 2025 because monoclonal antibody treatment often requires diagnosis, infusion, clinical monitoring and management of immune-related adverse events. Hospitals dominate oncology antibody administration, biologic initiation and inpatient management of severe disease. Specialty Centers are gaining demand because oncology centers, immunology clinics, neurology centers and infusion clinics can deliver targeted biologics in outpatient settings. Others include research institutions, diagnostic centers and home-care-linked specialty models. End-use growth will depend on infusion capacity, specialist availability, payer approval, cold-chain systems, physician confidence and patient support services.
Key Market Drivers
Rising oncology antibody demand
Rising oncology antibody demand represents a major growth driver for the Asia Pacific Monoclonal Antibodies Market. Cancer treatment increasingly depends on monoclonal antibodies, checkpoint inhibitors, antibody-drug conjugates and bispecific antibody platforms.
WHO estimates that the Western Pacific Region recorded close to 6.8 million new cancer cases in 2022, while WHO South-East Asia reported 2.37 million new cancer cases and 1.53 million cancer deaths in 2022. Supporting statement from key company data: Merck’s 2025 Form 10-K cited Japan approval of Keytruda with trastuzumab and chemotherapy for first-line HER2-positive gastric or gastroesophageal junction adenocarcinoma and China approval of Keytruda plus Lenvima with transarterial chemoembolization for unresectable, non-metastatic hepatocellular carcinoma. These developments support Oncology, Humanized and Human antibody demand across hospitals and specialty cancer centers.
Autoimmune disease biologic expansion
Autoimmune disease biologic expansion supports strong demand for monoclonal antibodies across chronic inflammatory conditions. Patients with psoriasis, inflammatory bowel disease, rheumatoid arthritis and related immune-mediated diseases increasingly use biologics after inadequate response to conventional treatment.
AbbVie reported full-year 2025 global immunology portfolio net revenues of USD 30.406 billion, including Skyrizi net revenues of USD 17.562 billion, Rinvoq net revenues of USD 8.304 billion and Humira net revenues of USD 4.540 billion. Johnson & Johnson also said Tremfya received Japan approvals in 2025 for moderate to severe ulcerative colitis and Crohn’s Disease and gained Japan approval in 2026 for subcutaneous ulcerative colitis induction therapy. This driver supports Autoimmune Diseases, Specialty Centers and hospital-led biologic initiation.
Antibody-drug conjugate and targeted oncology innovation
Antibody-drug conjugate and targeted oncology innovation is strengthening market value as companies introduce therapies that link antibody targeting with high-potency payloads. These products are increasing relevance for oncology monoclonal antibody platforms and expanding use beyond traditional antibody mechanisms.
AstraZeneca’s 2025 Form 20-F reported USD 1,798 million of Alliance Revenue related to Enhertu in 2025 and described Datroway as a TROP2-directed antibody-drug conjugate indicated in breast cancer and EGFR-mutated non-small cell lung cancer settings. Reuters also reported that Datroway was approved in Japan in December 2024 for a type of breast cancer after prior chemotherapy. These developments support Oncology, Humanized antibodies, hospitals and specialty oncology centers.
Regional approval momentum and portfolio expansion
Regional approval momentum and portfolio expansion support stronger adoption of monoclonal antibodies across Asia Pacific. Japan, China and other major markets continue to approve new indications and formats for oncology and autoimmune antibody therapies.
Bristol Myers Squibb’s 2025 filings cited Japan MHLW approval of Opdivo plus Yervoy in August 2025 for unresectable advanced or recurrent microsatellite instability-high colorectal cancer. Johnson & Johnson reported full-year 2025 results and highlighted significant innovation, including cancer therapy approvals and continuing data for antibody-based products such as Darzalex and Tremfya. This driver supports hospitals, specialty centers and broad antibody use across Oncology and Autoimmune Diseases.
Key Trends and Opportunities
Human and humanized antibodies gain preference
Human and humanized antibodies are gaining preference as developers focus on reducing immunogenicity and supporting long-term treatment. These formats are especially important in chronic autoimmune therapy and recurring oncology treatment where patients may need repeated dosing over long periods. Humanized and Human antibodies also support newer biologic formats, including checkpoint inhibitors and targeted immune therapies. Manufacturers that can combine efficacy, tolerability and convenient dosing will gain stronger physician acceptance. The trend supports premium product positioning across hospitals and specialty centers. It also reinforces demand for advanced cell culture production, quality control and biosimilar development capabilities.
Antibody-drug conjugates expand oncology use
Antibody-drug conjugates are expanding oncology use because they combine antibody targeting with cytotoxic payload delivery. This approach supports treatment in breast cancer, lung cancer, gastric cancer and other solid tumors where tumor-specific targeting improves therapeutic value. AstraZeneca and Daiichi Sankyo’s Enhertu and Datroway portfolios show how antibody-linked therapies are reshaping oncology growth. Asia Pacific is expected to gain from this trend because Japan and China remain important approval and commercialization markets. Hospitals and specialty oncology centers will remain the primary access points due to infusion requirements, monitoring needs and oncology expertise.
Specialty centers are strengthening outpatient biologic delivery as oncology, immunology and neurology care shifts toward structured infusion and injection models. These centers can improve patient throughput, reduce hospital burden and provide therapy-specific monitoring. Specialty Centers are especially relevant for Autoimmune Diseases, Neurological Diseases and maintenance oncology therapies. Growth will depend on payer approval, physician networks, cold-chain capability and patient support programs. Companies can expand access by partnering with specialty care networks and offering education on adverse event monitoring. This trend supports recurring treatment demand and improves continuity of care.
Key Market Challenges
High treatment cost and reimbursement barriers
High treatment cost and reimbursement barriers remain major challenges for the Asia Pacific Monoclonal Antibodies Market. Monoclonal antibodies often carry premium prices due to complex manufacturing, clinical development cost and specialty distribution requirements. Reimbursement varies widely across China, Japan, India, South Korea, Australia and Southeast Asia. Patients in lower-access markets may face out-of-pocket costs or delayed access to newer therapies. Hospitals and payers may restrict use to defined disease severity, biomarker status or post-failure settings. Manufacturers must support access programs, local evidence and pricing strategies to expand adoption.
Manufacturing complexity and cold-chain requirements
Manufacturing complexity and cold-chain requirements can limit supply reliability and increase cost. Monoclonal antibodies require cell culture systems, sterile processing, analytical testing, biologic quality controls and temperature-sensitive storage. Supply chains must maintain product integrity from manufacturing to hospital or specialty center administration. Antibody-drug conjugates add additional handling complexity due to high-potency payloads. Regional manufacturing investment can improve access, but regulatory compliance and scale-up remain demanding. Companies need robust quality systems, cold-chain monitoring and reliable distribution partnerships.
Biosimilar competition and originator price pressure
Biosimilar competition and originator price pressure affect established monoclonal antibody categories. Biosimilars can expand access in oncology and autoimmune diseases but reduce revenue for originator products. Payers may encourage biosimilar switching or tender-based purchasing to manage biologic spending. Physician confidence and patient acceptance can vary by country and indication. Originator companies must differentiate through new indications, improved formulations, subcutaneous delivery, combination therapy and real-world outcomes. Price pressure will remain significant as Asia Pacific markets expand biosimilar policies and local manufacturing capacity.
Regional Analysis
China
China represents a major opportunity within the Asia Pacific Monoclonal Antibodies Market due to its large cancer patient base, fast-growing biologics industry, increasing local manufacturing and expanding hospital oncology infrastructure. Oncology remains the leading application, supported by checkpoint inhibitors, HER2 antibodies, PD-1/PD-L1 therapies, VEGF inhibitors and antibody-drug conjugates. Autoimmune Diseases are also gaining traction as biologic reimbursement improves. Hospitals dominate use due to infusion requirements and specialist prescribing, while Specialty Centers are expanding in large urban markets. Growth will depend on national reimbursement, volume-based procurement, local biosimilar competition and innovation from domestic biotech companies.
Japan
Japan supports strong monoclonal antibody demand due to mature health care infrastructure, advanced oncology care, specialist reimbursement and early adoption of targeted therapies. Hospitals and Specialty Centers use monoclonal antibodies across Oncology, Autoimmune Diseases, Neurological Diseases and rare conditions. Japan remains strategically important for global companies because of its clinical sophistication, regulatory predictability and high acceptance of innovative biologics. Recent approvals for antibody-based oncology and autoimmune therapies reinforce demand in hospital and specialty settings. Growth will depend on reimbursement, aging population needs, biomarker testing, subcutaneous delivery and competition from biosimilars.
India
India is an expanding market supported by rising cancer diagnosis, autoimmune disease awareness, biosimilar production and private hospital growth. Monoclonal antibody access remains concentrated in major cities and tertiary hospitals due to cost, specialist requirements and infusion infrastructure. Oncology and Autoimmune Diseases are key applications, while biosimilars are expected to improve affordability over time. In Vitro production and domestic biologics manufacturing are becoming strategic advantages for India’s pharmaceutical industry. Growth will depend on insurance expansion, pricing, public procurement, physician confidence in biosimilars and wider availability of diagnostics.
South Korea
South Korea represents a high-value market supported by strong biomanufacturing, biosimilar leadership, advanced hospitals and rapid clinical adoption of biologics. Oncology and Autoimmune Diseases are the leading applications, while Neurological Diseases and specialty indications are gaining interest. Hospitals dominate antibody administration, but Specialty Centers support outpatient biologic therapy and chronic disease management. South Korea also plays a strategic role as a manufacturing and biosimilar export hub. Growth will depend on global partnerships, reimbursement, local manufacturing capacity, clinical trial activity and continued innovation in antibody formats.
Australia and New Zealand
Australia and New Zealand represent mature monoclonal antibody markets supported by structured reimbursement, specialist care pathways and evidence-based medicine adoption. Oncology, Autoimmune Diseases and Neurological Diseases support steady demand across hospitals and specialty centers. Public funding and national formularies shape access to high-cost antibody therapies. Biosimilar adoption is expected to improve affordability and free budget for newer therapies. Hospitals remain the leading end-use segment due to infusion and monitoring requirements. Growth will remain steady as clinical guidelines, biomarker testing and reimbursement decisions expand treatment eligibility.
Southeast Asia
Southeast Asia offers long-term growth potential as private hospital investment, cancer care capacity, biologics reimbursement and specialty center networks expand. Singapore leads advanced biologic adoption, while Thailand, Malaysia, Indonesia, Vietnam and the Philippines are increasing access at different speeds. Oncology and Autoimmune Diseases remain the main applications. Cost remains a major barrier, which supports demand for biosimilars and access programs. Hospitals remain the primary end-use segment, but Specialty Centers will grow in urban markets. Growth will depend on affordability, diagnostics, cold-chain logistics, reimbursement and physician training.
Report Attribute details
Report Attribute
Details
Historical Period
2021–2024
Base Year
2025
Forecast Period
2025–2032
Market Size in 2021
USD 40,541.17 MN
Market Size in 2025
USD 64,255.32 MN
Market Size in 2032
USD 149,792.56 MN
CAGR
10.70%
Segments Covered
Source Type, Production Type, Application, End Use and Geography
Key Companies Covered
Novartis AG, Pfizer Inc, Amgen Inc., GSK plc, Merck & Co., Inc., Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca plc, Eli Lilly And Company, Johnson & Johnson Services, Inc., Bayer AG, Bristol Myers Squibb Company and F. Hoffman-La Roche Ltd.
Asia Pacific Monoclonal Antibodies Market segmentations
By Source Type
Chimeric
Murine
Humanized
Human
By Production Type
In Vivo
In Vitro
By Application
Oncology
Autoimmune Diseases
Infectious Diseases
Neurological Diseases
Others
By End Use
Hospital
Specialty Centers
Others
Key Players
Novartis AG
Pfizer Inc
Amgen Inc.
GSK plc
Merck & Co., Inc.
Daiichi Sankyo Company, Limited
Abbott Laboratories
AstraZeneca plc
Eli Lilly And Company
Johnson & Johnson Services, Inc.
Bayer AG
Bristol Myers Squibb Company
F. Hoffman-La Roche Ltd.
Recent developments
In May 2025, Merck reported Japan MHLW approval of Keytruda with trastuzumab and chemotherapy for first-line HER2-positive gastric or gastroesophageal junction adenocarcinoma.
In June 2025, Merck reported China NMPA approval of Keytruda plus Lenvima with transarterial chemoembolization for unresectable, non-metastatic hepatocellular carcinoma.
In August 2025, Bristol Myers Squibb reported Japan MHLW approval of Opdivo plus Yervoy for unresectable advanced or recurrent microsatellite instability-high colorectal cancer.
In February 2026, Johnson & Johnson said Japan approved Tremfya subcutaneous formulation for induction therapy in moderate to severe ulcerative colitis after inadequate response to existing treatment.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The research report offers an in-depth analysis based on source type, production type, application, end use and geography. It details leading market players, providing an overview of their business positioning, monoclonal antibody portfolios, oncology antibodies, autoimmune biologics, antibody-drug conjugates, biosimilar exposure, manufacturing strategies and strategic relevance in the Asia Pacific Monoclonal Antibodies Market. The report includes insights into the competitive environment, market trends, growth drivers, restraints and opportunities. It also examines oncology treatment expansion, autoimmune biologic adoption, regional approvals, humanized antibody demand, In Vitro production, specialty center growth, biosimilar competition and cold-chain infrastructure as major factors shaping market development. The report assesses the impact of high treatment cost, reimbursement barriers, manufacturing complexity, biosimilar price pressure and country-specific access constraints on market growth. It provides strategic recommendations for pharmaceutical companies, hospitals, specialty centers, contract manufacturers, distributors, payers, investors and new entrants seeking to navigate Asia Pacific’s monoclonal antibody ecosystem.
Future Outlook
Demand for monoclonal antibodies will continue to rise as oncology and autoimmune treatment expands across Asia Pacific.
Humanized antibodies will remain a leading source type due to broad use in oncology and inflammatory disease treatment.
Human antibodies will gain momentum as developers prioritize lower immunogenicity and long-term tolerability.
In Vitro production will remain dominant because commercial antibody manufacturing requires scalable recombinant cell culture platforms.
Oncology will remain the leading application due to checkpoint inhibitors, HER2 antibodies, PD-1/PD-L1 antibodies and antibody-drug conjugates.
Autoimmune Diseases will grow as biologics expand in psoriasis, inflammatory bowel disease, rheumatoid arthritis and related conditions.
Neurological Diseases will gain relevance as antibody therapies expand in Alzheimer’s disease and immune-mediated neurological disorders.
Hospitals will remain the leading end-use segment due to infusion infrastructure, specialist oversight and monitoring needs.
Specialty Centers will gain share as outpatient infusion, oncology and immunology care models expand.
Competition will increase as companies compete on clinical evidence, biosimilar pricing, local manufacturing, access programs, subcutaneous delivery and regional approvals.
Table of Contents (The complete Toc, LoF and LoT are available in the sample report)
Chapter No. 1: Introduction
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. USP and Key Offerings
1.2. Key Benefits for Stakeholders
1.3. Target Audience
Chapter No. 2: Executive Summary
Chapter No. 3: Asia Pacific Monoclonal Antibodies Market forces and industry pulse
3.1. Introduction
3.2. Catalysts of Expansion – Key Market Drivers
3.2.1. Rising oncology antibody demand
3.2.2. Autoimmune disease biologic expansion
3.2.3. Antibody-drug conjugate and targeted oncology innovation
3.2.4. Regional approval momentum and portfolio expansion
3.3. Market Restraints
3.3.1. High treatment cost and reimbursement barriers
3.3.2. Manufacturing complexity and cold-chain requirements
3.3.3. Biosimilar competition and originator price pressure
3.4. Untapped Horizons – Growth Potential and Opportunities; Strategic Navigation – Industry Frameworks
3.4.1. Human and humanized antibodies gain preference
3.4.2. Antibody-drug conjugates expand oncology use
3.4.3. Specialty centers strengthen outpatient biologic delivery
Chapter No. 4: Competition Analysis
4.1. Company Market Share Analysis
4.1.1. Asia Pacific Monoclonal Antibodies Market Company Revenue Market Share, 2025
4.2. Strategic Developments
4.3. Competitive Dashboard
4.4. Company Assessment Metrics, 2025
Chapter No. 5: Asia Pacific Market Analysis, Insights and Forecast, by Source Type
Chapter No. 6: Asia Pacific Market Analysis, Insights and Forecast, by Production Type
Chapter No. 7: Asia Pacific Market Analysis, Insights and Forecast, by Application
Chapter No. 8: Asia Pacific Market Analysis, Insights and Forecast, by End Use
Chapter No. 9: Asia Pacific Market Analysis, Insights and Forecast, by Geography
9.1. China
9.2. Japan
9.3. India
9.4. South Korea
9.5. Australia and New Zealand
9.6. Southeast Asia
9.7. Rest of Asia Pacific
Chapter No. 10: Company Profile
10.1. Novartis AG
10.2. Pfizer Inc
10.3. Amgen Inc.
10.4. GSK plc
10.5. Merck & Co., Inc.
10.6. Daiichi Sankyo Company, Limited
10.7. Abbott Laboratories
10.8. AstraZeneca plc
10.9. Eli Lilly And Company
10.10. Johnson & Johnson Services, Inc.
10.11. Bayer AG
10.12. Bristol Myers Squibb Company
10.13. F. Hoffman-La Roche Ltd.
List of figures
Fig No. 1: Asia Pacific Monoclonal Antibodies Market Revenue Share, by Source Type, 2025 and 2032
Fig No. 2: Market Attractiveness Analysis, by Source Type
Fig No. 3: Incremental Revenue Growth Opportunity by Source Type, 2025–2032
Fig No. 4: Asia Pacific Monoclonal Antibodies Market Revenue Share, by Production Type, 2025 and 2032
Fig No. 5: Incremental Revenue Growth Opportunity by Production Type, 2025–2032
Fig No. 6: Asia Pacific Monoclonal Antibodies Market Revenue Share, by Application, 2025 and 2032
Fig No. 7: Asia Pacific Monoclonal Antibodies Market Revenue Share, by End Use, 2025 and 2032
Fig No. 8: Asia Pacific Monoclonal Antibodies Market Revenue Share, by Geography, 2025 and 2032
Fig No. 9: Market Attractiveness Analysis, by Geography
List of tables
Table No. 1: Asia Pacific Monoclonal Antibodies Market Revenue, by Source Type, 2021–2025 (USD MN)
Table No. 2: Asia Pacific Monoclonal Antibodies Market Revenue, by Source Type, 2026–2032 (USD MN)
Table No. 3: Asia Pacific Monoclonal Antibodies Market Revenue, by Production Type, 2021–2025 (USD MN)
Table No. 4: Asia Pacific Monoclonal Antibodies Market Revenue, by Production Type, 2026–2032 (USD MN)
Table No. 5: Asia Pacific Monoclonal Antibodies Market Revenue, by Application, 2021–2025 (USD MN)
Table No. 6: Asia Pacific Monoclonal Antibodies Market Revenue, by Application, 2026–2032 (USD MN)
Table No. 7: Asia Pacific Monoclonal Antibodies Market Revenue, by End Use, 2021–2025 (USD MN)
Table No. 8: Asia Pacific Monoclonal Antibodies Market Revenue, by End Use, 2026–2032 (USD MN)
Table No. 9: Asia Pacific Monoclonal Antibodies Market Revenue, by Geography, 2021–2025 (USD MN)
Table No. 10: Asia Pacific Monoclonal Antibodies Market Revenue, by Geography, 2026–2032 (USD MN)
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for the Asia Pacific Monoclonal Antibodies Market and what is its projected size in 2032?
The Asia Pacific Monoclonal Antibodies Market was valued at USD 64,255.32 MN in 2025 and is projected to reach USD 149,792.56 MN by 2032.
At what CAGR is the Asia Pacific Monoclonal Antibodies Market projected to grow?
The Asia Pacific Monoclonal Antibodies Market is projected to grow at a CAGR of 10.70% during the forecast period.
Which source type segment is expected to lead the market?
Humanized antibodies are expected to hold a strong position because they are widely used across oncology and autoimmune treatment and offer lower immunogenicity than murine formats.
Which application supports strong market demand?
Oncology supports strong market demand because cancer care increasingly uses checkpoint inhibitors, antibody-drug conjugates, bispecific antibodies and targeted monoclonal antibody combinations.
Which production type holds the strongest position?
In Vitro holds the strongest position because commercial monoclonal antibody production relies on controlled cell culture systems and scalable recombinant expression platforms.
Who are the leading companies in the market?
The leading companies include Novartis AG, Pfizer Inc, Amgen Inc., GSK plc, Merck & Co., Inc., Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca plc, Eli Lilly And Company, Johnson & Johnson Services, Inc., Bayer AG, Bristol Myers Squibb Company and F. Hoffman-La Roche Ltd.
Which countries are important in the Asia Pacific market?
China, Japan, India, South Korea, Australia, New Zealand and Southeast Asian countries are important markets due to cancer burden, biologics manufacturing, specialty care access, biosimilar adoption and growing approval activity.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Africa Orphan Drugs Market size was valued at USD 792.75 MN in 2021 and reached USD 1,258.16 MN in 2025. It is anticipated to reach USD 2,826.51 MN by 2032, growing at a CAGR of 6.30% during the forecast period.
The Middle East Vaccines Market size was valued at USD 873.98 MN in 2021 and reached USD 1,325.11 MN in 2025. It is anticipated to reach USD 2,813.55 MN by 2032, growing at a CAGR of 9.44% during the forecast period.
The Africa Biosimilars Market size was valued at USD 126.63 MN in 2021 and reached USD 200.98 MN in 2025. It is anticipated to reach USD 451.50 MN by 2032, growing at a CAGR of 7.80% during the forecast period.
The Direct to Consumer Testing Market size was estimated at USD 9,820.35 million in 2025 and is expected to reach USD 16,891.17 million by 2032, growing at a CAGR of 9.46% from 2025 to 2032.
The Asia Pacific Biologics Market size was valued at USD 36,980.76 MN in 2021 and reached USD 50,912.57 MN in 2025. It is anticipated to reach USD 92,757.72 MN by 2032, growing at a CAGR of 7.50% during the forecast period.
The Europe Dermatology Drugs Market size was valued at USD 8,384.62 MN in 2021 and reached USD 10,909.79 MN in 2025. It is anticipated to reach USD 17,933.36 MN by 2032, growing at a CAGR of 6.18% during the forecast period.
The North America Pain Management Drugs Market size was valued at USD 11,968.20 MN in 2021 and reached USD 14,314.26 MN in 2025. It is anticipated to reach USD 18,345.24 MN by 2032, growing at a CAGR of 2.85% during the forecast period.
The Direct to Consumer Laboratory Testing Market size was estimated at USD 7,250.90 million in 2025 and is expected to reach USD 13,430.77 million by 2032, growing at a CAGR of 10.82% from 2025 to 2032.
The North America Respiratory Drugs Market size was valued at USD 4,603.33 MN in 2021 and reached USD 5,912.29 MN in 2025. It is anticipated to reach USD 8,990.65 MN by 2032, growing at a CAGR of 5.07% during the forecast period.
The North America CNS Drugs Market size was valued at USD 29,971.81 MN in 2021 and reached USD 39,376.62 MN in 2025. It is anticipated to reach USD 64,694.22 MN by 2032, growing at a CAGR of 6.13% during the forecast period.
The Asia Pacific Gastrointestinal Drugs Market size was valued at USD 14,076.07 MN in 2021 and reached USD 18,379.23 MN in 2025. It is anticipated to reach USD 27,675.57 MN by 2032, growing at a CAGR of 4.86% during the forecast period.
The Asia Pacific Cancer Biopsy Market size was valued at USD 2,917.45 MN in 2021 and reached USD 4,124.28 MN in 2025. It is anticipated to reach USD 8,097.12 MN by 2032, growing at a CAGR of 8.52% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
